Trials / Completed
CompletedNCT02864121
Oncogenous HPV DNA Integration (Intégration De l'ADN Des HPV Oncogènes)
Association Between High-risk HPV Genome Integration Detected by Molecular Combing and Cervical Lesions Severity and/or Evolution
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 407 (actual)
- Sponsor
- CHU de Reims · Academic / Other
- Sex
- Female
- Age
- 25 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
High-risk human papillomavirus (HR-HPV) are involved in cervical cancer development. Integration of HR-HPV DNA in cellular genomes is considered as a major event in the cervical cancer development. The aim of this study is to validate the integration of the HPV-HR as an appropriate biomarker of the severity of precancerous lesions and progression of cervical lesions towards cervical cancer. HR-HPV integration status will be analyzed by Molecular Combing technology, which allows direct and high-resolution visualization of the integration of high-risk HPV genomes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | all patients included in IDAHO study |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2018-12-17
- Completion
- 2019-12-17
- First posted
- 2016-08-11
- Last updated
- 2020-06-16
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02864121. Inclusion in this directory is not an endorsement.